IMMUTEP Ltd — Investor Relations & Filings

Immutep Ltd. is a late clinical-stage biotechnology company developing novel immunotherapies for cancer and autoimmune diseases. As a pioneer in its field, the company focuses on therapeutics related to Lymphocyte Activation Gene-3 (LAG-3), a cell surface molecule that plays a vital role in regulating the immune system. Immutep's diversified portfolio is designed to harness LAG-3 to either stimulate the immune response to fight cancer or modulate it to combat autoimmune diseases. Its lead product candidate is eftilagimod alfa, a soluble LAG-3 fusion protein under investigation in multiple oncology trials. The company maintains a pipeline of several clinical-stage assets targeting areas of high unmet medical need.